Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy

Bibliography

• Gabriel SE, Crowson CS, Kremers HM, Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8
   PubMed Web of Science ®Google Scholar
• Symmons DP, Jones MA, Scott DL, Prior P. Long term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25(6):1072-7
   PubMed Web of Science ®Google Scholar
• Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd edition. Oxford University Press; New York: 2001
   Google Scholar
• Boyer GS, Benevolenskaya LI, Templin DW, Prevalence of rheumatoid arthritis in circumpolar native populations. J Rheumatol 1998;25:23-9
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36:182-8
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, Is the incidence of rheumatoid arthritis rising? : results from olmsted county, minnesota, 1955 – 2007. Arthritis Rheum 2010;62(6):1576-82
   PubMed Web of Science ®Google Scholar
• Symmons D, Turner G, Webb R, The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793-800
   PubMed Web of Science ®Google Scholar
• Allaire S, Wolfe F, Niu J, Lavalley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 2008;59(4):474-80
   PubMed Web of Science ®Google Scholar
• Pincus T, Callahan LF, Sale WG, Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72
   PubMed Web of Science ®Google Scholar
• Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999;26:1681-5
   PubMed Web of Science ®Google Scholar
• Wolfe FE, Hawley DJ. The longterm outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients. J Rheumatol 1998;25:2108-17
   PubMed Web of Science ®Google Scholar
• Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7
   PubMed Web of Science ®Google Scholar
• Dominick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life among older adults with arthritis. Health Qual Life Outcomes 2004;2(1):5
   PubMedGoogle Scholar
• Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13
   PubMed Web of Science ®Google Scholar
• Kallberg H, Padyukov L, Plenge RM, Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80(5):867-75
   PubMed Web of Science ®Google Scholar
• van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50(3):709-15
   PubMed Web of Science ®Google Scholar
• Meyer O, Nicaise-Roland P, Santos MD, Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006;8(2):R40
   PubMedGoogle Scholar
• Stolt P, Bengtsson C, Nordmark B, Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62(9):835-41
   PubMed Web of Science ®Google Scholar
• Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology 2010;49(9):1618-31
   PubMed Web of Science ®Google Scholar
• Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008;8:533-44
   PubMed Web of Science ®Google Scholar
• Cornish AL, Campbell IK, McKenzie BS, G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):554-9
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440
   PubMed Web of Science ®Google Scholar
• Singh JA, Pando JA, Tomaszewski J, Schumacher HR. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug and corticosteroid-naive patients. J Rheumatol 2004;31:1281-5
   PubMed Web of Science ®Google Scholar
• Xu WD, Firestein GS, Taetle R, Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 1989;83(3):876-82
   PubMed Web of Science ®Google Scholar
• Fiehn C, Wermann M, Pezzutto A, Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy. Z Rheumatol 1992;51:121-6
   PubMed Web of Science ®Google Scholar
• Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39(1):115-24
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Baeten D, Firestein GS, Synovial tissue analysis in clinical trials. J Rheumatol 2005;32:2481-4
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Gerlag DM, Zwinderman AH, Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Pontifex E, Thurlings RM, Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol 2009;36:1800-2
   PubMed Web of Science ®Google Scholar
• Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony stimulating factor exacerbates collagen-induced arthritis in mice. Ann Rheum Dis 1997;56:364-8
   PubMed Web of Science ®Google Scholar
• Cook AD, Braine EL, Campbell IK, Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 2001;3(5):293-8
   PubMedGoogle Scholar
• Nakano K, Okada Y, Saito K, Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:597-603
   PubMed Web of Science ®Google Scholar
• Alsalameh S, Firestein GS, Oez S, Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor. J Rheumatol 1994;21(6):993-1002
   PubMed Web of Science ®Google Scholar
• Lloyd S, Bujkiewicz S, Wailoo AJ, The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010;49(12):2313-21
   PubMed Web of Science ®Google Scholar
• Emery P, Furst DE, Ferraccioli G, Repeated treatment courses of rituximab produce sustained efficacy in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs. Arthritis Rheum 2007;56(Suppl 9):s151
   Google Scholar
• Emery P, Keystone E, Tony HP, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23
   PubMed Web of Science ®Google Scholar
• Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989;74:2769-70
   PubMed Web of Science ®Google Scholar
• Cohen S, Eghobamien L, Sims D, In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody for the treatment of patients with rheumatoid arthritis. Arthritis Rheum 2008;58(9 Suppl):S665
   Web of Science ®Google Scholar
• Cohen S, McCourt M, Monk P, Functional in vivo Blockade of the GM-CSF Receptor in Cynomolgus Monkey with CAM-3001, A Human Anti-GM-CSF Receptor Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis [Abs 133P]. British Pharmacological Society Winter Meeting; 2009
   Google Scholar
• Burmester GR, Feist E, Sleeman MA, Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011;70:1542-9
   PubMed Web of Science ®Google Scholar
• Wang B, Lau YY, Liang M, Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis. J Clin Pharmacol 2012;52(8):1150-61
   PubMed Web of Science ®Google Scholar
• Burmester GR, Weinblatt ME, Barbarash O, Mavrilimumab (an Anti-GM-CSFRalpha Monoclonal Antibody) in Subjects with Rheumatoid Arthritis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study. Oral presentation at the American college of Rheumatology Annual Scientific Meeting; 8 November 2011
   Google Scholar